Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372420 | PMC |
http://dx.doi.org/10.47895/amp.v58i14.11353 | DOI Listing |
Ann Med Surg (Lond)
October 2024
Department of Pathology, Golsar Hospital, Rasht, Guilan, Iran.
Sci Rep
September 2024
Laboratory of Soil Mechanics, Swiss Federal Institute of Technology, Lausanne, Switzerland.
Acta Med Philipp
August 2024
National Teacher Training Center for the Health Professions, University of the Philippines Manila.
Breast Cancer Res
June 2024
The Ben May Department for Cancer Research, The University of Chicago, 929 East 57th Street GCIS W421C, Chicago, IL, 60637, USA.
Background: Breast cancers treated with aromatase inhibitors (AIs) can develop AI resistance, which is often driven by estrogen receptor-alpha (ERα/ESR1) activating mutations, as well as by ER-independent signaling pathways. The breast ER antagonist lasofoxifene, alone or combined with palbociclib, elicited antitumor activities in a xenograft model of ER + metastatic breast cancer (mBC) harboring ESR1 mutations. The current study investigated the activity of LAS in a letrozole-resistant breast tumor model that does not have ESR1 mutations.
View Article and Find Full Text PDFEnviron Health Perspect
May 2024
Departments of Epidemiology and Environmental and Occupational Health, Colorado School of Public Health, Aurora, Colorado, USA.
Background: In response to the COVID-19 pandemic, new evidence-based strategies have emerged for reducing transmission of respiratory infections through management of indoor air.
Objectives: This paper reviews critical advances that could reduce the burden of disease from inhaled pathogens and describes challenges in their implementation.
Discussion: Proven strategies include assuring sufficient ventilation, air cleaning by filtration, and air disinfection by germicidal ultraviolet (UV) light.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!